CD8A and neoplasm: CTL killing of tumor targets requires T-cell recognition of specific major histocompatibility complex (MHC) Class I/CD8+-restricted epitope complexes on the surface of tumor cells, an event determined by the cooperative interactions of multiple antigen-processing machinery (APM) components.